Online Program Home
My Program

CC = Colorado Convention Center   H = Hyatt Regency Denver at Colorado Convention Center
* = applied session       ! = JSM meeting theme

Activity Details

130 Mon, 7/29/2019, 8:30 AM - 10:20 AM CC-112
Statistical Methods for Time-To-Event Data and Applications — Contributed Papers
Biopharmaceutical Section
Chair(s): Ruvie Martin, Novartis Pharmaceuticals
8:35 AM Tools to Compare Restricted Mean Survival Times in Randomized Controlled Studies with Small Sample Data
Miki Horiguchi, Kitasato University; Hajime Uno, Dana-Farber Cancer Institute
8:50 AM Survival Analysis in the Absence of Proportional Hazards: Defining the Relevant Null Hypothesis

Steven Snapinn, Alder Biopharmaceuticals; Qi Jiang, Seattle Genetics
9:05 AM Modeling the Impact of Dose Intervention on Time-To-Event Outcomes
Amir Nikooienejad, Eli Lilly and Company; Yongming Qu, Eli Lilly and Company
9:20 AM A Flexible Parametric Survival Model for Fitting Time-to-Event Data in Clinical Trials

Jason Liao, Merck & Co. Inc.; Frank G Liu, Merck Sharp & Dohme Inc.
9:35 AM Teasing Out the Overall Survival Benefit with Adjustment for Treatment Switching to Other Therapies

Meijing Wu, AbbVie; Weili He, AbbVie; Qiming Liao, VIIV Health Care; Yabing Mai, AbbVie
9:50 AM An Approach to Increase Power in Immuno-Oncology Trials When Non-Proportional Hazard Is Present

Nan Jia, Sanofi US
10:05 AM Evaluating Methods for Correcting the Impact of Treatment Switching on Overall Survival
Jin Zhang